1.31
+0.16(+13.91%)
Currency In USD
| Previous Close | 1.15 |
| Open | 1.19 |
| Day High | 1.31 |
| Day Low | 1.16 |
| 52-Week High | 14.4 |
| 52-Week Low | 1.09 |
| Volume | 108,899 |
| Average Volume | 3.63M |
| Market Cap | 10.28M |
| PE | 0.02 |
| EPS | 56.32 |
| Moving Average 50 Days | 1.37 |
| Moving Average 200 Days | 2.31 |
| Change | 0.16 |
If you invested $1000 in Ernexa Therapeutics Inc. (ERNA) 10 years ago, it would be worth $0.29 as of December 05, 2025 at a share price of $1.31. Whereas If you bought $1000 worth of Ernexa Therapeutics Inc. (ERNA) shares 5 years ago, it would be worth $1.04 as of December 05, 2025 at a share price of $1.31.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Dec 03, 2025 1:30 PM GMT
CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that data from its novel cell
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG
GlobeNewswire Inc.
Dec 02, 2025 1:50 PM GMT
Appointment reinforces clinical and translational depth as Ernexa advances its best-in-class iMSC cell therapy platform into first-in-human trialsCAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry in
Ernexa Therapeutics to Present at Oxford Global’s Cell 2025
GlobeNewswire Inc.
Nov 11, 2025 12:00 PM GMT
Sanjeev Luther, President and CEO to give an oral presentation and participate in a moderated panel discussionCAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therap